 |
Previous Article | Next Article 
The Journal of Neuroscience, 2002, 22:RC209:1-5
RAPID COMMUNICATION
Lack of Tumor Necrosis Factor-Related Apoptosis-Inducing
Ligand But Presence of Its Receptors in the Human Brain
Jan
Dörr1, *,
Ingo
Bechmann2, *,
Sonia
Waiczies1, *,
Orhan
Aktas1,
Henning
Walczak3,
Peter H.
Krammer4,
Robert
Nitsch2, *, and
Frauke
Zipp1, *
1 Department of Neurology, Division of Neuroimmunology
and 2 Institute of Anatomy, Department of Cell- and
Neurobiology, Charité Neuroscience Research Center, 10098 Berlin,
Germany, and Divisions of 3 Apoptosis Regulation and
4 Immunogenetics, Tumour Immunology, German Cancer Research
Center, 69009 Heidelberg, Germany
Apoptosis mediated by members of the tumor necrosis factor
(TNF)-nerve growth factor superfamily plays a crucial role in
the interaction of the nervous and the immune system. On the one hand, it is involved in the defense mechanisms of the brain, the immune privilege. On the other hand, it is involved in the induction of
glial-neuronal cell death in neuroinflammatory diseases. Here, we show
that in contrast to the other known death ligands, TNF-related apoptosis-inducing ligand (TRAIL) is not constitutively expressed in
the human brain, whereas both apoptosis-mediating and
apoptosis-blocking TRAIL receptors are found on neurons, astrocytes,
and oligodendrocytes. Thus, the brain differs from other
immune-privileged organs, such as the placenta, with the TRAIL
receptor-TRAIL system not being part of the immune privilege of the
brain. Conversely, this death receptor-ligand system might well play
an important role in T cell-mediated autoimmune diseases of the
CNS such as multiple sclerosis.
Key words:
TRAIL; TRAIL receptor; apoptosis; immune privilege; brain; MS
*
J.D., I.B., S.W., R.N., and
F.Z. contributed equally to this work.
Correspondence should be addressed to Dr. Frauke Zipp, Department of
Neurology, Division of Neuroimmunology, Neuroscience Research Center
NWFZ 2680, Charité Campus Mitte, Schumannstrasse 20/21, 10117 Berlin, Germany. E-mail: frauke.zipp{at}charite.de.
Copyright © Society for Neuroscience 0270-6474//$05.00/0
This article has been cited by other articles:

|
 |

|
 |
 
M. Candolfi, K. Yagiz, D. Foulad, G. E. Alzadeh, M. Tesarfreund, A.K.M. G. Muhammad, M. Puntel, K. M. Kroeger, C. Liu, S. Lee, et al.
Release of HMGB1 in Response to Proapoptotic Glioma Killing Strategies: Efficacy and Neurotoxicity
Clin. Cancer Res.,
July 1, 2009;
15(13):
4401 - 4414.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Y. Huang, N. Erdmann, H. Peng, S. Herek, J. S. Davis, X. Luo, T. Ikezu, and J. Zheng
TRAIL-Mediated Apoptosis in HIV-1-Infected Macrophages Is Dependent on the Inhibition of Akt-1 Phosphorylation
J. Immunol.,
August 15, 2006;
177(4):
2304 - 2313.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
T. Murata, M. Tsuboi, K. Hikita, and N. Kaneda
Protective Effects of Neurotrophic Factors on Tumor Necrosis Factor-related Apoptosis-inducing Ligand (TRAIL)-mediated Apoptosis of Murine Adrenal Chromaffin Cell Line tsAM5D
J. Biol. Chem.,
August 11, 2006;
281(32):
22503 - 22516.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
N Arbour, E Rastikerdar, E McCrea, Y Lapierre, J Dorr, A Bar-Or, and J P Antel
Upregulation of TRAIL expression on human T lymphocytes by interferon b and glatiramer acetate
Multiple Sclerosis,
December 1, 2005;
11(6):
652 - 657.
[Abstract]
[PDF]
|
 |
|

|
 |

|
 |
 
D. C. Spierings, E. G. de Vries, E. Vellenga, F. A. van den Heuvel, J. J. Koornstra, J. Wesseling, H. Hollema, and S. de Jong
Tissue Distribution of the Death Ligand TRAIL and Its Receptors
J. Histochem. Cytochem.,
June 1, 2004;
52(6):
821 - 831.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Y. Miura, N. Misawa, Y. Kawano, H. Okada, Y. Inagaki, N. Yamamoto, M. Ito, H. Yagita, K. Okumura, H. Mizusawa, et al.
Tumor necrosis factor-related apoptosis-inducing ligand induces neuronal death in a murine model of HIV central nervous system infection
PNAS,
March 4, 2003;
100(5):
2777 - 2782.
[Abstract]
[Full Text]
[PDF]
|
 |
|
|

|